EurekaMag
+ Most Popular
Cunninghamia lanceolata plantations in China
Mammalian lairs in paleo ecological studies and palynology
Studies on technological possibilities in utilization of anhydrous milk fat for production of recombined butter-like products
Should right-sided fibroelastomas be operated upon?
Large esophageal lipoma
Apoptosis in the mammalian thymus during normal histogenesis and under various in vitro and in vivo experimental conditions
Poissons characoides nouveaux ou non signales de l'Ilha do Bananal, Bresil
Desensitizing efficacy of Colgate Sensitive Maximum Strength and Fresh Mint Sensodyne dentifrices
Administration of fluid by subcutaneous infusion: revival of a forgotten method
Tundra mosquito control - an impossible dream?
Schizophrenia for primary care providers: how to contribute to the care of a vulnerable patient population
Geochemical pattern analysis; method of describing the Southeastern limestone regional aquifer system
Incidence of low birth weights in a hospital of Mexico City
Tabanidae
Graded management intensity of grassland systems for enhancing floristic diversity
Microbiology and biochemistry of cheese and fermented milk
The ember tetra: a new pygmy characid tetra from the Rio das Mortes, Brazil, Hyphessobrycon amandae sp. n. (Pisces, Characoidei)
Risk factors of contrast-induced nephropathy in patients after coronary artery intervention
Renovation of onsite domestic wastewater in a poorly drained soil
Observations of the propagation velocity and formation mechanism of burst fractures caused by gunshot
Systolic blood pressure in a population of infants in the first year of life: the Brompton study
Haematological studies in rats fed with metanil yellow
Studies on pasteurellosis. I. A new species of Pasteurella encountered in chronic fowl cholera
Dormancy breaking and germination of Acacia salicina Lindl. seeds
therapy of lupus nephritis. a two-year prospective study

Live attenuated varicella vaccine in healthy 12- to 24-month-old children


Live attenuated varicella vaccine in healthy 12- to 24-month-old children



Pediatrics 81(4): 512-518



ISSN/ISBN: 0031-4005

PMID: 2832819

We studied live attenuated Oka/Merck varicella vaccine in 147 seronegative children 12 to 24 months of age and their 94 seronegative older siblings 2 to 12 years of age. The vaccine side effects were mild, consisting of a papular rash in 15 of 147 (10.2%) children 12 to 24 months and seven of 94 (7.4%) siblings. In a subset of 12- to 24-month-old children, modified fluorescent antibody test for membrane antigen was not detectable at seven days postimmunization but was detectable in 50% by 14 days and in 100% by 21 days. Within 6 weeks, 96.6% of children 12 to 24 months and 94.7% of siblings seroconverted. The geometric mean titer did not vary with age at immunization. One-year blood samples were obtained from 70 children 12 to 24 months of age who seroconverted; 92.9% retained detectable antibody. The geometric mean titer had decreased from 55.7 to 18.6. Of these 70 children, 34% had been exposed to varicella since immunization, and two cases of varicella were observed in seroconverters. Both cases were mild, with less than 50 vesicles. Oka/Merck varicella vaccine appears to be safe, highly immunogenic, and protective against 96% of exposures to natural varicella during the first year after vaccination in infants. Those cases of varicella that develop in immunized children appear substantially reduced in severity.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 040584885

Download citation: RISBibTeXText

Related references

Live attenuated varicella vaccine in healthy 12 24 month old children. Pediatric Research 19(4 Part 2): 296A, 1985

Evaluation of a live attenuated varicella vaccine in 15- to 18-month-old healthy children. Zhonghua Minguo Xiao Er Ke Yi Xue Hui Za Zhi Zhonghua Minguo Xiao Er Ke Yi Xue Hui 39(1): 38-42, 1998

Evaluation of live attenuated varicella vaccine (Oka-RIT strain) and combined varicella and MMR vaccination in 13-17-month-old children. Acta Paediatrica Scandinavica 80(11): 1051-1057, 1991

Live attenuated varicella vaccine: protection in healthy adults compared with leukemic children. National Institute of Allergy and Infectious Diseases Varicella Vaccine Collaborative Study Group. Journal of Infectious Diseases 161(4): 661-666, 1990

High incidence of breakthrough varicella observed in healthy Japanese children immunized with live attenuated varicella vaccine (Oka strain). Acta Paediatrica Japonica: Overseas Edition 39(6): 663-668, 1997

Safety and immunogenicity of live attenuated varicella vaccine in 9-month-old children. Pediatrics International: Official Journal of the Japan Pediatric Society 42(6): 674-677, 2000

Live attenuated varicella vaccine: the KMcC strain in healthy children. Pediatrics 71(3): 307-312, 1983

Immunogenicity and safety of a live attenuated varicella vaccine (Oka/SB Bio) in healthy children. Journal of Infectious Diseases 174(Suppl): S324-S329, 1996

Immunization of healthy children with live attenuated varicella vaccine (OKA strain). Kansenshogaku Zasshi. Journal of the Japanese Association for Infectious Diseases 60(12): 1311-1316, 1986

Live attenuated varicella vaccine: immunization of healthy children with the OKA strain. Journal of Pediatrics 100(6): 886-893, 1982

Dose titration study of live attenuated varicella vaccine in healthy children. The Journal of Infectious Diseases 175(2): 444-447, 1997

Live attenuated varicella virus vaccine: efficacy trial in healthy children. The new England Journal of Medicine 310(22): 1410-1415, 1984

Clinical trial of the Oka strain of live attenuated varicella vaccine on healthy children. Biken Journal 27(2-3): 39-42, 1984

Live attenuated varicella virus vaccine. Efficacy trial in healthy children. New England Journal of Medicine 310(22): 1409-1415, 1984

Efficacy of high-titer live attenuated varicella vaccine in healthy young children. Journal of Infectious Diseases 174(Suppl): S330-S334, 1996